Early anti-thrombotic and anti-inflammatory actions of statins and fibrates - Time for adjuvant therapy in acute coronary syndromes?

Thrombosis and Haemostasis

Volumn 94, Issue 1, 2005, Pages 1-3

  Damås, Jan Kristian ^a   Puccetti, Luca ^b   Aukrust, Pål ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; CD40 LIGAND; CHEMOKINE; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DOWN REGULATION; EDITORIAL; ENZYME INHIBITION; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION;

ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; BLOOD PLATELETS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DOWN-REGULATION; FIBRINOLYTIC AGENTS; GLUCOSE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; THROMBOSIS; TIME FACTORS;

EID: 22144474798     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-0317     Document Type: Editorial

References (22)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Libby P. Current consepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
3. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-7.
4. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation 2002; 105: 2937-8.
5. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
6. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92.
7. Lazar MA. Progress in cardiovascular biology: PPAR for the course. Nat Med 2001; 7: 23-4.
8. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21: 1891-5.
9. Marx N, Kehrle B, Kohlhammer K et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-10.
10. Despres JP, Lemieux I, Pascot A et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2003; 23: 702-3.
11. Undas A, Celinska-Lowenhoff M, Domagala TB et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005; 93: 193-9.
12. Buffon A, Biasucci LM, Liuzzo G et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
13. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-62.
14. Wibaut-Berlaimont V, Randi AM, Mandryko V et al. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 2005; 3: 677-85.
15. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004; 15: 637-43.
16. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
17. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
18. Anand SX, Viles-Gonzalez JF, Badimon JJ et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
19. Furman MI, Krueger LA, Linden MD et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43: 2319-25.
20. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-20.
21. Puccetti L, Pasqui AL, Pastorelli M et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 2002; 32: 901-8.
22. Puccetti L, Sawamura T, Pasqui AL et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolemic patients. Eur J Clin Invest 2005; 35: 47-51.